select a format

Single User License
USD 2000 INR 128580
Site License
USD 4000 INR 257160
Corporate User License
USD 6000 INR 385740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Genital Herpes-Pipeline Review, H1 2017

Genital Herpes-Pipeline Review, H1 2017


  • Products Id :- GMDHC9088IDB
  • |
  • Pages: 102
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Genital Herpes-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes-Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Genital Herpes-Overview

Genital Herpes-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Genital Herpes-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Genital Herpes-Companies Involved in Therapeutics Development

Abivax SA

Admedus Ltd

AiCuris GmbH & Co KG

Biomere LLC

Foamix Pharmaceuticals Ltd

Genocea Biosciences Inc

GenVec Inc

Immune Design Corp

JN-International Medical Corp

N & N Pharmaceuticals Inc

NanoBio Corp

NanoViricides Inc

Profectus BioSciences Inc

Redbiotec AG

Sanofi Pasteur SA

Starpharma Holdings Ltd

Tomegavax Inc

Vaccibody AS

Vaxart Inc

Vical Inc

Genital Herpes-Drug Profiles

ABX-196-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acyclovir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEN-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GV-2207-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus [type 1, 2] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSV-529-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pritelivir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Genital Herpes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCLHB-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCLHM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTMX-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Genital Herpes-Dormant Projects

Genital Herpes-Discontinued Products

Genital Herpes-Product Development Milestones

Featured News & Press Releases

Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine

Jan 05, 2017: Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial

Dec 14, 2016: Genocea R&D Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs & Strategy

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Oct 28, 2016: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016

Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data

Sep 29, 2016: Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial

Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits

Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months

Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016

Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing

Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging

Feb 03, 2016: Model helps decide drug dose for clinical testing

Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003

Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Genital Herpes, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Genital Herpes, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Genital Herpes-Pipeline by Abivax SA, H1 2017

Genital Herpes-Pipeline by Admedus Ltd, H1 2017

Genital Herpes-Pipeline by AiCuris GmbH & Co KG, H1 2017

Genital Herpes-Pipeline by Biomere LLC, H1 2017

Genital Herpes-Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Genital Herpes-Pipeline by Genocea Biosciences Inc, H1 2017

Genital Herpes-Pipeline by GenVec Inc, H1 2017

Genital Herpes-Pipeline by Immune Design Corp, H1 2017

Genital Herpes-Pipeline by JN-International Medical Corp, H1 2017

Genital Herpes-Pipeline by N & N Pharmaceuticals Inc, H1 2017

Genital Herpes-Pipeline by NanoBio Corp, H1 2017

Genital Herpes-Pipeline by NanoViricides Inc, H1 2017

Genital Herpes-Pipeline by Profectus BioSciences Inc, H1 2017

Genital Herpes-Pipeline by Redbiotec AG, H1 2017

Genital Herpes-Pipeline by Sanofi Pasteur SA, H1 2017

Genital Herpes-Pipeline by Starpharma Holdings Ltd, H1 2017

Genital Herpes-Pipeline by Tomegavax Inc, H1 2017

Genital Herpes-Pipeline by Vaccibody AS, H1 2017

Genital Herpes-Pipeline by Vaxart Inc, H1 2017

Genital Herpes-Pipeline by Vical Inc, H1 2017

Genital Herpes-Dormant Projects, H1 2017

Genital Herpes-Dormant Projects, H1 2017 (Contd..1), H1 2017

Genital Herpes-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abivax SA, Admedus Ltd, AiCuris GmbH & Co KG, Biomere LLC, Foamix Pharmaceuticals Ltd, Genocea Biosciences Inc, GenVec Inc, Immune Design Corp, JN-International Medical Corp, N & N Pharmaceuticals Inc, NanoBio Corp, NanoViricides Inc, Profectus BioSciences Inc, Redbiotec AG, Sanofi Pasteur SA, Starpharma Holdings Ltd, Tomegavax Inc, Vaccibody AS, Vaxart Inc, Vical Inc

Genital Herpes Therapeutic Products under Development, Key Players in Genital Herpes Therapeutics, Genital Herpes Pipeline Overview, Genital Herpes Pipeline, Genital Herpes Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com